Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Makes key senior appointments.
January 17, 2020
By: Tim Wright
Editor-in-Chief, Contract Pharma
Catalent has appointed Karen Flynn as president of biologics and chief commercial officer. Ms. Flynn has also joined the company’s executive leadership team and will report to Alessandro Maselli, Catalent’s president and chief operating officer. Ms. Flynn takes on the role previously held by Mr. Barry Littlejohns, who will be retiring. Ms. Flynn assumes global responsibility for Catalent’s biologics business, including the several investments and expansions currently taking place, which include a $200 million capital investment to expand drug substance manufacturing capacity in Madison, WI and drug product fill/finish capacity in Bloomington, IN. Ms. Flynn will also spearhead commercial excellence across the entire company. In addition, Catalent has promoted Mike Riley to region president, biologics North America, and appointed Manja Boerman as region president, biologics Europe, where each will lead all development, manufacturing, and commercial activity in their respective regions, as well as growing Catalent Biologics’ business. Mr. Riley has been with Catalent for nearly 15 years and previously served as vice president/general manager of Catalent Biologics. In his new role, Mr. Riley will oversee the sites in Bloomington and Madison, as well as Emeryville, CA, and the company’s biologics operations at its facilities in Research Triangle Park, NC, and Kansas City, MO. Ms. Boerman joined Catalent in December 2019 from her previous role as president of Aesica Pharmaceuticals, and has over 20 years’ experience in biotech and pharmaceutical services. She will oversee the company’s European biologics sites, including Brussels, Belgium and its newly acquired site in Anagni, Italy, which is a state-of-the-art facility for late-phase tech transfers and commercial product launches. Pete Buzy will continue to lead Catalent’s gene therapy business, where, under his guidance, Catalent has been investing significantly in capacity, equipment, and expertise needed to meet strong and growing demand for custom development and manufacturing of adeno-associated virus (AAV) vectors, next-generation vaccines, and oncolytic viruses. Ms. Flynn has over 30 years’ experience in commercial, operations, and general management roles within the pharmaceutical services industry, and she rejoins Catalent after more than 11 years, having previously spent eight years as part of Cardinal Health/Catalent in various commercially focused roles. Her most recent position was senior vice president and chief commercial officer for West Pharmaceutical Services. “We welcome Karen back to Catalent in a role that allows her to use her extensive talents and experience as we deliver to our customers advanced, crucial pharmaceutical research and development services, as well as commercial supply,” said Mr. Maselli. “Karen arrives during a period of strong growth both in the biologics business and across the company as a whole, during which we are investing hundreds of millions of dollars in our biologics business and strengthening our commitment to ensuring that our customers have access to the best possible advanced biologic development technology and manufacturing solutions, from DNA through to clinical and commercial supply.” He added, “We would like to thank Barry, who has given more than three decades of service to the company and, in particular, led our initial efforts to expand our biologics drug substance, drug product, and gene therapy businesses.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !